GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (OTCPK:NRXBF) » Definitions » ROE %

NRXBF (NurExone Biologic) ROE % : -181.72% (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is NurExone Biologic ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. NurExone Biologic's annualized net income for the quarter that ended in Sep. 2024 was $-5.00 Mil. NurExone Biologic's average Total Stockholders Equity over the quarter that ended in Sep. 2024 was $2.75 Mil. Therefore, NurExone Biologic's annualized ROE % for the quarter that ended in Sep. 2024 was -181.72%.

The historical rank and industry rank for NurExone Biologic's ROE % or its related term are showing as below:

NRXBF' s ROE % Range Over the Past 10 Years
Min: -509.78   Med: -314.87   Max: -139.88
Current: -210.63

During the past 3 years, NurExone Biologic's highest ROE % was -139.88%. The lowest was -509.78%. And the median was -314.87%.

NRXBF's ROE % is ranked worse than
90.04% of 1305 companies
in the Biotechnology industry
Industry Median: -43.68 vs NRXBF: -210.63

NurExone Biologic ROE % Historical Data

The historical data trend for NurExone Biologic's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic ROE % Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23
ROE %
-139.93 -499.18 -318.51

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -656.56 -647.91 -193.09 -170.80 -181.72

Competitive Comparison of NurExone Biologic's ROE %

For the Biotechnology subindustry, NurExone Biologic's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NurExone Biologic's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's ROE % distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's ROE % falls into.



NurExone Biologic ROE % Calculation

NurExone Biologic's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-3.639/( (2.096+0.189)/ 2 )
=-3.639/1.1425
=-318.51 %

NurExone Biologic's annualized ROE % for the quarter that ended in Sep. 2024 is calculated as

ROE %=Net Income (Q: Sep. 2024 )/( (Total Stockholders Equity (Q: Jun. 2024 )+Total Stockholders Equity (Q: Sep. 2024 ))/ count )
=-5/( (2.575+2.928)/ 2 )
=-5/2.7515
=-181.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. ROE % is displayed in the 30-year financial page.


NurExone Biologic  (OTCPK:NRXBF) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-5/2.7515
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-5 / 0)*(0 / 3.453)*(3.453 / 2.7515)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.255
=ROA %*Equity Multiplier
=N/A %*1.255
=-181.72 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-5/2.7515
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-5 / -5) * (-5 / -5.14) * (-5.14 / 0) * (0 / 3.453) * (3.453 / 2.7515)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9728 * N/A % * 0 * 1.255
=-181.72 %

Note: The net income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


NurExone Biologic ROE % Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


NurExone Biologic Business Description

Traded in Other Exchanges
Address
1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.